(Q28211411)

English

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

scientific article

In more languages

Statements

scholarly article

0 references

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial (English)

0 references

randomized controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michael Doherty

object named as

Michael Doherty

5

0 references

author name string

Thomas J Schnitzer

1

0 references

Gerd R Burmester

2

0 references

Eduardo Mysler

3

0 references

Marc C Hochberg

4

0 references

Elena Ehrsam

6

0 references

Xavier Gitton

7

0 references

Gerhard Krammer

8

0 references

Bernhard Mellein

9

0 references

Patrice Matchaba

10

0 references

Alberto Gimona

11

0 references

Christopher J Hawkey

12

0 references

language of work or name

0 references

publication date

August 2004

1 reference

0 references

364

0 references

665-74

0 references

9435

0 references

Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal safety of coxibs and outcomes studies: what's the verdict?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective cyclooxygenase-2 inhibitors: similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Problems associated with the clinical use of proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Review article: the development of atrophic gastritis--Helicobacter pylori and the effects of acid suppressive therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(04)16893-1

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28211411&oldid=1516220817"